Core Insights - AccuStem Sciences, Inc. and EmeritusDX are expanding their strategic partnership to commercialize the MSC test for lung cancer screening, aiming to improve accuracy in lung nodule stratification and reduce healthcare costs [1][3] - The MSC test analyzes 24 microRNAs to differentiate between high- and low-risk lung nodules, facilitating earlier patient care and potentially minimizing unnecessary procedures [2] - The operational deployment of the MSC test is planned for launch in US clinics in 2026, with both companies pursuing reimbursement strategies to enhance access for the 1.6 million patients diagnosed annually with lung nodules in the US [3] Company Overview - AccuStem is focused on optimizing outcomes and quality of life for cancer patients through proprietary molecular testing that addresses unmet clinical needs from screening to treatment [5] - EmeritusDX specializes in delivering actionable clinical information and operates a world-class laboratory that supports cancer diagnosis and treatment [7] Leadership Statements - Wendy Blosser, CEO of AccuStem, emphasized the significance of the MSC test in lung cancer screening technology and the potential for impactful diagnostic solutions [4] - Robert Embree, CEO of EmeritusDX, expressed excitement about the collaboration and the commitment to expanding access to innovative diagnostics for cancer patients [4]